Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients
Therapeutic Advances in Medical Oncology
Published online on May 14, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Sorafenib, an oral multikinase inhibitor, was the first systemic therapy to demonstrate an overall survival benefit in advanced hepatocellular carcinoma (HCC). Gastrointestinal (GI) adverse events (AE), particularly diarrhea, nausea, and ...
Background:Sorafenib, an oral multikinase inhibitor, was the first systemic therapy to demonstrate an overall survival benefit in advanced hepatocellular carcinoma (HCC). Gastrointestinal (GI) adverse events (AE), particularly diarrhea, nausea, and ...